Table 3 Logit Models: Predicting Respondents Who Would Choose a Medicine for Herself
From: Preferences for breast cancer prevention among women with a BRCA1 or BRCA2 mutation
Characteristic | All Women (N = 598), OR (95% CI) | Women Assigned to See Medicine 1, a Denosumab-Like Medicine (n = 289), OR (95% CI) | Women Assigned to See Medicine 2, a Tamoxifen-Like Medicine (n = 309), OR (95% CI) |
|---|---|---|---|
Age 40 years or over | 0.953 (0.563–1.614) | 1.446 (0.678–3.083) | 0.651 (0.298–1.423) |
Hopes to have children in future (after mutation identified) or undecided | 0.792 (0.468–1.338) | 0.772 (0.354–1.683) | 0.806 (0.380–1.711) |
Time since genetic test | 1.051* (1.007–1.097) | 1.095* (1.029–1.165) | 1.014 (0.952–1.080) |
First-degree relative with breast cancer | 0.962 (0.657–1.409) | 0.821 (0.474–1.422) | 1.086 (0.627–1.879) |
First-degree relative with ovarian cancer | 1.240 (0.795–1.935) | 1.401 (0.736–2.669) | 1.305 (0.681–2.498) |
RRBM only | 0.693 (0.398–1.207) | 1.284 (0.538–3.063) | 0.468* (0.220–0.996) |
RRBSO only | 0.753 (0.408–1.390) | 0.951 (0.385–2.349) | 0.546 (0.224–1.331) |
RRBM and RRBSO | 0.383* (0.211–0.697) | 0.331* (0.134–0.816) | 0.424* (0.182–0.987) |
Higher education | 0.843 (0.573–1.241) | 0.933 (0.524–1.663) | 0.761 (0.440–1.316) |
Has taken a prescription medication, such as tamoxifen, raloxifene, or an aromatase inhibitor [anastrazole, exemestane] | 2.524* (1.198–5.316) | 1.683 (0.565–5.015) | 3.506* (1.214–10.124) |